- AI in Health Care and Biotechnology: Promise, Progress, and Challenges Foley & Lardner LLP
- AI in Biotechnology Market to Reach $11.4 Billion by 2030 Yahoo Finance
- From wild fungi to faster drug discovery Drug Target Review
- AI giants Nvidia, Microsoft and Google are making critical moves in pharma R&D PharmaVoice
- Artificial Intelligence in Drug Discovery Market 2025-2032: Trends, Growth Drivers & Global Forecast PharmiWeb.com
Category: 3. Business
-
AI in Health Care and Biotechnology: Promise, Progress, and Challenges – Foley & Lardner LLP
-
Access Denied
Access Denied
You don’t have permission to access “http://www.mastercard.com/us/en/news-and-trends/press/2025/october/Mastercard-introduces-first-ever-threat-intelligence-solution.html” on this server.
Reference #18.d9b31402.1761583326.6ad9acdc
https://errors.edgesuite.net/18.d9b31402.1761583326.6ad9acdc
Continue Reading
-
Hyundai Motor Group and Toray Group Strengthen Ties to Develop Advanced Materials for Future Mobility
- Hyundai Motor Group and Toray Group to develop advanced materials for future mobility, including high-performance vehicles and special-purpose mobility
- Hyundai Motor Group will carry out vehicle-level design, performance evaluation and suitability assessments of advanced materials and components
- Toray Group will focus on developing intermediate materials and molded products based on its carbon fiber technologies
- The two companies will collaborate across the entire value chain in the field of high-performance composites, from R&D to production and commercialization
SEOUL, October 27, 2025 – Hyundai Motor Group and Toray Industries, Inc. (Toray Group) signed a Strategic Joint Development Agreement to collaborate on advanced materials and components innovation, aiming to set new standards in future mobility.The signing ceremony took place on October 24 at Hyundai Motor Group’s headquarters in Seoul, Korea. Key attendees included Heung-soo Kim, Executive Vice President and Head of Global Strategy Office at Hyundai Motor Group and Miki Terada, General Manager of Advanced Composites Division at Toray Group.
“This agreement marks an important milestone in our partnership, as it represents the first tangible outcome of our strategic collaboration initiated last year,” said EVP Kim. “By clearly defining our focus areas and combining our respective strengths, we will work closely together across the entire process—from R&D to production and commercialization—in the field of advanced composite materials, enhancing our ability to respond to market demands.”
Miki Terada, General Manager of Advanced Composites Division at Toray Group, also commented that “The Joint Development Agreement marks a significant step forward in advancing the partnership established in the previous year. Leveraging Toray’s unique material technologies and extensive expertise, we will collaborate closely with Hyundai Motor Group to create innovative composite solutions essential for next-generation mobility. From R&D to production and commercialization, we will work in close coordination to enhance our competitiveness in the global market.”
Building on the strategic cooperation agreement signed in April 2024, the two companies have continued to work together to develop high-performance composite materials, such as carbon fiber-reinforced plastic (CFRP), to enhance safety and performance in mobility.
Since then, the two companies have identified projects that maximize synergy through close collaboration and have outlined concrete plans for joint development by leveraging their respective strengths.
The newly signed agreement represents a major step forward in their collaboration, accelerating the development of advanced materials and components for future mobility, including high-performance vehicles as well as special-purpose mobility such as lunar exploration rovers and robots.
Hyundai Motor Group aims to accelerate innovation in future mobility and create new market opportunities through close collaboration with Toray Group across the entire value chain—from technology development to production and commercialization—in the field of high-performance composite materials.
As part of this effort, Hyundai Motor Group will carry out vehicle-level design, suitability assessments and performance evaluations of advanced materials and components through its Materials Research & Engineering Center, which is responsible for developing and validating new body materials.
The development and production of carbon fiber composites will be carried out by Toray Group’s global subsidiaries: Toray Advanced Materials Korea, Toray Advanced Composites in the Netherlands and Euro Advanced Carbon Fiber Composites in Germany. These entities focus on developing intermediate materials and molded products based on Toray Group’s carbon fiber technology.
– End –
About Toray
Toray is a leading technology and advanced materials innovator. We have contributed to social progress since our foundation in 1926 by creating new values. We help the world to overcome new challenges by supplying fibers and textiles, resins and films, carbon fiber composite materials, and other high value-added products. Our 306 subsidiaries and affiliates worldwide employ almost 48,000 people.About Hyundai Motor Group
Hyundai Motor Group is a global enterprise that has created a value chain based on mobility, steel, and construction, as well as logistics, finance, IT, and service. With about 250,000 employees worldwide, the Group’s mobility brands include Hyundai, Kia, and Genesis. Armed with creative thinking, cooperative communication, and the will to take on any challenges, we strive to create a better future for all.More information about Hyundai Motor Group can be found at: http://www.hyundaimotorgroup.com or Newsroom: Media Hub by Hyundai, Kia Global Media Center (kianewscenter.com), Genesis Newsroom
Contact:
Kyeongjin Kim
Global PR Strategy & Planning / Hyundai Motor Group
kyeongjin.kim@hyundai.comContinue Reading
-
Hyundai Motor Group and Toray Group Strengthen Ties to Develop Advanced Materials for Future Mobility
- Hyundai Motor Group and Toray Group to develop advanced materials for future mobility, including high-performance vehicles and special-purpose mobility
- Hyundai Motor Group will carry out vehicle-level design, performance evaluation and suitability assessments of advanced materials and components
- Toray Group will focus on developing intermediate materials and molded products based on its carbon fiber technologies
- The two companies will collaborate across the entire value chain in the field of high-performance composites, from R&D to production and commercialization
SEOUL, October 27, 2025 – Hyundai Motor Group and Toray Industries, Inc. (Toray Group) signed a Strategic Joint Development Agreement to collaborate on advanced materials and components innovation, aiming to set new standards in future mobility.The signing ceremony took place on October 24 at Hyundai Motor Group’s headquarters in Seoul, Korea. Key attendees included Heung-soo Kim, Executive Vice President and Head of Global Strategy Office at Hyundai Motor Group and Miki Terada, General Manager of Advanced Composites Division at Toray Group.
“This agreement marks an important milestone in our partnership, as it represents the first tangible outcome of our strategic collaboration initiated last year,” said EVP Kim. “By clearly defining our focus areas and combining our respective strengths, we will work closely together across the entire process—from R&D to production and commercialization—in the field of advanced composite materials, enhancing our ability to respond to market demands.”
Miki Terada, General Manager of Advanced Composites Division at Toray Group, also commented that “The Joint Development Agreement marks a significant step forward in advancing the partnership established in the previous year. Leveraging Toray’s unique material technologies and extensive expertise, we will collaborate closely with Hyundai Motor Group to create innovative composite solutions essential for next-generation mobility. From R&D to production and commercialization, we will work in close coordination to enhance our competitiveness in the global market.”
Building on the strategic cooperation agreement signed in April 2024, the two companies have continued to work together to develop high-performance composite materials, such as carbon fiber-reinforced plastic (CFRP), to enhance safety and performance in mobility.
Since then, the two companies have identified projects that maximize synergy through close collaboration and have outlined concrete plans for joint development by leveraging their respective strengths.
The newly signed agreement represents a major step forward in their collaboration, accelerating the development of advanced materials and components for future mobility, including high-performance vehicles as well as special-purpose mobility such as lunar exploration rovers and robots.
Hyundai Motor Group aims to accelerate innovation in future mobility and create new market opportunities through close collaboration with Toray Group across the entire value chain—from technology development to production and commercialization—in the field of high-performance composite materials.
As part of this effort, Hyundai Motor Group will carry out vehicle-level design, suitability assessments and performance evaluations of advanced materials and components through its Materials Research & Engineering Center, which is responsible for developing and validating new body materials.
The development and production of carbon fiber composites will be carried out by Toray Group’s global subsidiaries: Toray Advanced Materials Korea, Toray Advanced Composites in the Netherlands and Euro Advanced Carbon Fiber Composites in Germany. These entities focus on developing intermediate materials and molded products based on Toray Group’s carbon fiber technology.
– End –
About Toray
Toray is a leading technology and advanced materials innovator. We have contributed to social progress since our foundation in 1926 by creating new values. We help the world to overcome new challenges by supplying fibers and textiles, resins and films, carbon fiber composite materials, and other high value-added products. Our 306 subsidiaries and affiliates worldwide employ almost 48,000 people.About Hyundai Motor Group
Hyundai Motor Group is a global enterprise that has created a value chain based on mobility, steel, and construction, as well as logistics, finance, IT, and service. With about 250,000 employees worldwide, the Group’s mobility brands include Hyundai, Kia, and Genesis. Armed with creative thinking, cooperative communication, and the will to take on any challenges, we strive to create a better future for all.More information about Hyundai Motor Group can be found at: http://www.hyundaimotorgroup.com or Newsroom: Media Hub by Hyundai, Kia Global Media Center (kianewscenter.com), Genesis Newsroom
Contact:
Kyeongjin Kim
Global PR Strategy & Planning / Hyundai Motor Group
kyeongjin.kim@hyundai.comContinue Reading
-

IDWeek 2025: novel phage AP-SA02 leads to earlier resolution of S. aureus bacteremia
At IDWeek 2025, held on 19–22 October, Dr Loren Miller from Harbor-UCLA Medical Center/Lundquist Institute presented efficacy and safety data from a Phase Ib/IIa randomised, placebo-controlled trial investigating Armata Pharmaceuticals’ intravenous bacteriophage cocktail, AP-SA02, in adult patients with bacteremia caused by Staphylococcus aureus.
Bacteriophages, or phages, are viruses that can selectively target and kill bacteria. They work by infecting specifically targeted bacteria with phage DNA. This allows the phage to replicate inside of the host cell, produce phage offspring, and then lyse the bacterial cell to release the new phages. Phages are particularly advantageous anti-infectives as they are novel therapeutics, can target antibiotic-resistant bacteria, can be used as monotherapy or combination therapy, and do not cause microbiome disruption in patients.
S. aureus is a commensal bacterium and part of the natural human microbiome in approximately 30% of people. Conversely, S. aureus can lead to serious infections, particularly in those with chronic health conditions, in intensive care units (ICUs), or with weakened immune systems. Staphylococcus aureus bacteremia (SAB) can lead to serious bloodstream infections, including cellulitis, sepsis, and endocarditis. The World Health Organization (WHO) categorised methicillin-resistant S. aureus (MRSA) as a high-priority pathogen in the 2024 WHO Bacterial Priority Pathogens List.
The Phase IIa portion of the diSArm trial (NCT05184764) included 42 patients who were 18 years of age or older and had been hospitalized and diagnosed with a positive blood culture for S. aureus. These patients were randomised into two groups: those receiving intravenous AP-SA02 at a dose of 2×10¹⁰ plaque forming units (PFU) or 5×10¹⁰ PFU every six hours for five days, in addition to intravenous standard of care (SOC) best available antibiotic therapy (BAT) for 14–56 days, or those in the placebo group receiving SOC BAT for 14–56 days. Test-of-cure (TOC) screenings were performed seven days after the end of AP-SA02 (Day 12), seven days after the end of BAT (Day 18–60), and 28 days after the end of BAT (Day 39–81).
The site of infections in the patients in the study included septic joint, cellulitis, osteomyelitis, pneumonia, sepsis, and endocarditis; 19 of the patients tested positive for MRSA. The BAT antibiotics included cefazolin, vancomycin, oxacillin/nafcillin, daptomycin, cefepime, and ceftriaxone; some patients received more than one antibiotic.
At all TOC screenings, the clinical response in patients receiving AP-SA02 plus BAT was higher than in patients who had received the placebo plus BAT, including in patients with MRSA and methicillin-susceptible S. aureus (MSSA). On average, the AP-SA02 plus BAT–treated patients observed an initial resolution of their SAB infection in 2.7 days, compared to 9.3 days in the placebo plus BAT–treated group. Additionally, the AP-SA02 plus BAT–treated patients were discharged from the hospital after approximately 11.7 days and had a mean C-reactive protein level of 50.2mg/l on Day 12, compared to 19.2 days and 97.3mg/l, respectively, in the placebo plus BAT group.
Overall, AP-SA02 was found to be generally safe and well tolerated. Adverse events (AEs) were observed in 66% of patients who received the AP-SA02 plus BAT therapy, and treatment-emergent AEs (TEAEs) were observed in 59% of these patients. Only one patient was reported as having study drug–related TEAEs. One patient death was reported in the AP-SA02 plus BAT group, but this was found to be unrelated to infection, the study drug, or the BAT antibiotic.
The results of the Phase IIa trial support AP-SA02’s advancement into Phase III development. Armata Pharmaceuticals plans to initiate this pivotal study in 2026. The clinical success of AP-SA02 highlights its potential to fulfil a critical need for SAB patients.
Continue Reading
-
FIF – PRS – Raiffeisen Bank Serbia (EFSD+2)
Understanding transition
Further information regarding the EBRD’s approach to measuring transition impact is available here.
Business opportunities
For business opportunities or procurement, contact the client company.
For business opportunities with the EBRD (not related to procurement) contact:
Tel: +44 20 7338 7168
Email: projectenquiries@ebrd.comFor state-sector projects, visit EBRD Procurement:
Tel: +44 20 7338 6794
Email: procurement@ebrd.comGeneral enquiries
Specific enquiries can be made using the EBRD Enquiries form.
Environmental and Social Policy (ESP)
The ESP and its associated Environmental and Social Requirements (ESRs) set out the ways in which the EBRD implements its commitment to promoting “environmentally sound and sustainable development”. The ESP and the ESRs include specific provisions for clients to comply with the applicable requirements of national laws on public information and consultation, and to establish a grievance mechanism to receive and facilitate resolution of stakeholders’ concerns and grievances, in particular, about the environmental and social (E&S) performance of the client and the project. Proportionate to the nature and scale of a project’s environmental and social risks and impacts, the EBRD also requires its clients to disclose information, as appropriate, about the risks and impacts of projects or to undertake meaningful consultation with stakeholders and consider and respond to their feedback.
More information on the EBRD’s practices in this regard is set out in the ESP.
Integrity and compliance
The EBRD’s Office of the Chief Compliance Officer (OCCO) promotes good governance and ensures that the highest standards of integrity are applied to all of the Bank’s activities in accordance with international best practice. Integrity due diligence is conducted on all Bank clients to ensure that projects do not present unacceptable integrity or reputational risks to the Bank. The EBRD believes that identifying and resolving issues in the project assessment and approval stages is the most effective means of ensuring the integrity of Bank transactions. OCCO plays a key role in these protective efforts andhelps to monitor integrity risks in projects post-investment.
OCCO is further responsible for investigating allegations of fraud, corruption and misconduct in EBRD-financed projects. Anyone, either within or outside the Bank, who suspects fraud or corruption should submit a written report to the Chief Compliance Officer by email to compliance@ebrd.com. OCCO will follow-up all matters reported. It will review all matters reported. Reports can be made in any language of the Bank or of the Bank’s countries of operation. The information provided must be made in good faith.
Access to Information Policy (AIP)
The AIP, which entered into force on 1 January 2025, sets out how the EBRD discloses information and consults with its stakeholders to promote better awareness and understanding of its strategies, policies and operations. Please visit the Access to Information Policy page to find out what information is available from the EBRD website.
Specific requests for information can be made using the EBRD enquiries form.
Independent Project Accountability Mechanism (IPAM)
If efforts to address environmental, social or public disclosure concerns with the Client or the Bank are unsuccessful (for example, through the client’s project-level grievance mechanism or through direct engagement with Bank management), individuals and organisations may seek to address their concerns through the EBRD’s Independent Project Accountability Mechanism (IPAM).
IPAM independently reviews project issues that are believed to have caused (or to be likely to cause) harm. The purpose of the mechanism is: to support dialogue between project stakeholders to resolve environmental, social and public disclosure issues; to determine whether the Bank has complied with its Environmental and Social Policy or the project-specific provisions of its Access to Information Policy; and where applicable, to address any existing non-compliance with these policies, while preventing future non-compliance by the Bank.
Please visit the Independent Project Accountability Mechanism webpage to find out more about IPAM and its mandate and how to submit a Request for review. Alternatively, contact IPAM by email at ipam@ebrd.com for guidance and more information on IPAM and how to submit a request.
Continue Reading
-

iPhone demand improving in China, Jefferies says
Investing.com — Apple’s iPhone demand in China is showing signs of recovery, according to Jefferies analyst Edison Lee, which said growth in the world’s second-largest economy “has accelerated,” challenging its earlier negative outlook.
Lee told investors that his firm’s tracking shows “continued shortening in lead time in all models and markets, with only a few exceptions.”
He added that “17P’s lead time has almost disappeared and 17 Air in China also saw lead time fall to nearly zero,” while “the base model still shows the strongest trend in lead time.”
Despite shorter delivery times, Jefferies stated that “industry checks suggest growth in China has accelerated.”
The firm estimated that “for the first five weeks since iPhone 17 shipment started, total iPhone unit growth reached 19% year over year,” a figure it described as “very impressive” and one that “continues to challenge our negative view on AAPL.”
However, Jefferies warned that the recent momentum could come at the expense of profitability.
“While volume growth may be better than expected, we remain concerned about the risk of margin miss, given aggressive pricing in the base model of 17 and lack of ASP increase for 17 PM despite higher BOM costs,” wrote Lee.
The analyst also pointed to a “material shrinkage in resale premium” across all iPhone 17 variants, noting that “all variants of 17 Pro finally went into discounts from premium, which is the first time since launch.”
Jefferies concluded that while China and Hong Kong “show the strongest demand among the six markets we track,” product mix and rising memory costs “would create margin risk in 2026 for the entire smartphone industry.”
Related articles
iPhone demand improving in China, Jefferies says
Qualcomm stock jumps after unveiling new AI chips to challenge Nvidia
Trump narrows Fed chair candidates to five finalists
Continue Reading
-
Exclusive: US Department of Energy forms $1 billion supercomputer and AI partnership with AMD – Reuters
- Exclusive: US Department of Energy forms $1 billion supercomputer and AI partnership with AMD Reuters
- U.S. establishes $1bn supercomputer and AI partnership with AMD, Reuters reports Investing.com
- AMD, HP Enterprise, Oracle working on DOE supercomputers, Reuters reports TipRanks
- US Department of Energy partners with AMD on $1B supercomputing initiative Proactive financial news
- AMD rises as CEO, Energy Secretary disclosed $1B partnership for supercomputers MSN
Continue Reading
-

ECRS Mk1 adds key capabilities to Eurofighter Tranche 5
ECRS Mk1 is the next-generation Eurofighter radar system that will be put into service with the German and Spanish Air Forces. Based on multi-channel AESA technology and a high-end processor, ECRS Mk1 will further enhance the capabilities of the Eurofighter. The architecture of the ECRS Mk1 has been developed to enhance the entire spectrum of combat aircraft missions, including advanced air-to-air and high-resolution air-to-ground capabilities, as well as passive and active electronic warfare capabilities. In total approximately 200 ECRS Mk1 will be delivered to the German and Spanish Air Forces.
Continue Reading
